^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TQB2618
i
Other names: TQB2618
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sino Biopharm
Drug class:
TIM-3 inhibitor
Related drugs:
2ms
TQB2618-AK105-Ib-03: Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P1/2, N=75, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2024 --> Dec 2024
Enrollment open • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
cisplatin • paclitaxel • Anniko (penpulimab) • TQB2618
11ms
A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. (clinicaltrials.gov)
P1, N=75, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Jan 2024
Enrollment open • Trial initiation date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Focus V (anlotinib) • Anniko (penpulimab) • TQB2618
over1year
A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. (clinicaltrials.gov)
P1, N=75, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1 trial • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Focus V (anlotinib) • Anniko (penpulimab) • TQB2618
over1year
Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma (clinicaltrials.gov)
P1, N=50, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
Loqtorzi (toripalimab-tpzi) • TQB2618
over1year
Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P1/2, N=75, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1/2 trial • Metastases
|
PD-L1 (Programmed death ligand 1)
|
cisplatin • paclitaxel • Anniko (penpulimab) • TQB2618
2years
Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=127, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1/2 trial • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
PD-L1 expression • ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation
|
Andewei (benmelstobart) • TQB2618
2years
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
P2, N=110, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
cisplatin • gemcitabine • Anniko (penpulimab) • TQB2618
over2years
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Pembrolizumab in the Treatment of Patients With Relapsed and Refractory Lymphoma (clinicaltrials.gov)
P1/2, N=92, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1/2 trial
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
Keytruda (pembrolizumab) • Anniko (penpulimab) • TQB2618
Share via
